GlassScriptPhysician profile
Katelyn H Call
NPI 1699217810
$2,918.74
in general payments reported to CMS, 2019-2025
22 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $490 · 2022: $782 · 2023: $645 · 2024: $575 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,273.67 | 2021-2025 | |
| Amgen INC. | $245.30 | 2021-2024 | Repatha |
| Pfizer INC. | $233.82 | 2021-2025 | |
| Abbott Laboratories | $227.69 | 2023-2024 | Mitraclip, Navitor, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $163.85 | 2021-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $134.05 | 2021-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $103.85 | 2022-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $65.54 | 2024-2025 | |
| Novo Nordisk INC | $54.76 | 2024 | Wegovy, Rybelsus, Ozempic |
| Regeneron Healthcare Solutions, INC. | $48.50 | 2022-2023 | Evkeeza, Praluent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.14 | 2023-2024 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $42.79 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $41.90 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $41.42 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.87 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $34.99 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.03 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $21.93 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $18.40 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $17.80 | 2022 | |
| Atricure, INC. | $16.86 | 2023 | |
| Cvrx, INC. | $12.58 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Call listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.